Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogenous, white suspension in the vaccine container. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration [see Description (11)]. This product should not be used if particulate matter or discoloration is found.
Do not mix Prevnar 13 with other vaccines/products in the same syringe.
For intramuscular injection only.
Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age.
| Dose | Dose 1*,† | Dose 2† | Dose 3† | Dose 4‡ |
|---|---|---|---|---|
| Age at Dose | 2 months | 4 months | 6 months | 12–15 months |
For children 7 months through 5 years of age who have not received Prevnar or Prevnar 13, the catch-up schedule in Table 2 applies:
| Age at First Dose | Total Number of 0.5 mL Doses |
|---|---|
| 7–11 months of age | 3* |
| 12–23 months of age | 2† |
| 24 months through 5 years of age (prior to the 6th birthday) | 1 |
The immune responses induced by this catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 4 doses of Prevnar 13 (given at 2, 4, 6, and 12–15 months). In children 24 months through 5 years of age, lower antibody concentrations were observed for some serotypes, compared to antibody concentrations following 3 doses of Prevnar 13 (given at 2, 4, and 6 months).
Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogenous, white suspension in the vaccine container. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration [see Description (11)]. This product should not be used if particulate matter or discoloration is found.
Do not mix Prevnar 13 with other vaccines/products in the same syringe.
For intramuscular injection only.
Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age.
| Dose | Dose 1*,† | Dose 2† | Dose 3† | Dose 4‡ |
|---|---|---|---|---|
| Age at Dose | 2 months | 4 months | 6 months | 12–15 months |
For children 7 months through 5 years of age who have not received Prevnar or Prevnar 13, the catch-up schedule in Table 2 applies:
| Age at First Dose | Total Number of 0.5 mL Doses |
|---|---|
| 7–11 months of age | 3* |
| 12–23 months of age | 2† |
| 24 months through 5 years of age (prior to the 6th birthday) | 1 |
The immune responses induced by this catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 4 doses of Prevnar 13 (given at 2, 4, 6, and 12–15 months). In children 24 months through 5 years of age, lower antibody concentrations were observed for some serotypes, compared to antibody concentrations following 3 doses of Prevnar 13 (given at 2, 4, and 6 months).
Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogenous, white suspension in the vaccine container. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration [see Description (11)]. This product should not be used if particulate matter or discoloration is found.
Do not mix Prevnar 13 with other vaccines/products in the same syringe.
For intramuscular injection only.
Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age.
| Dose | Dose 1*,† | Dose 2† | Dose 3† | Dose 4‡ |
|---|---|---|---|---|
| Age at Dose | 2 months | 4 months | 6 months | 12–15 months |
For children 7 months through 5 years of age who have not received Prevnar or Prevnar 13, the catch-up schedule in Table 2 applies:
| Age at First Dose | Total Number of 0.5 mL Doses |
|---|---|
| 7–11 months of age | 3* |
| 12–23 months of age | 2† |
| 24 months through 5 years of age (prior to the 6th birthday) | 1 |
The immune responses induced by this catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 4 doses of Prevnar 13 (given at 2, 4, 6, and 12–15 months). In children 24 months through 5 years of age, lower antibody concentrations were observed for some serotypes, compared to antibody concentrations following 3 doses of Prevnar 13 (given at 2, 4, and 6 months).
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.